INTRODUCTION
Mitochondrial carnitine palmitoyltransferase (CPT) allows the incorporation of activated long-chain fatty acids (LCFAs) into the mitochondria, where they will be catabolized through β-oxidation. The first reaction, between the acyl-CoA molecule and carnitine, is catalysed by CPT I and takes place on the outside of the mitochondrial membrane, generating free CoA and acylcarnitine. The second reaction, between acylcarnitine and CoA, takes place in the matrix and is catalysed by CPT II on the inside of the inner membrane. The acyl-CoA generated is the substrate for the β-oxidation pathway. Two isotypes of CPT I have been described and are referred to as liver (L-) CPT I and muscle (M-) CPT I, based on the tissues of origin, in which the expression of these genes was first studied [1] .
It is generally accepted that the CPT I isotypes are the main locus of control for LCFA oxidation, because these enzymes are sensitive to inhibition by malonyl-CoA. CPT II appears to have a more limited role, since it is not inhibited by this lipogenic intermediate [1] . However, induction of CPT II gene expression has been observed in starved mice [2] and in animals fed with a high-fat diet or peroxisome proliferators [3] [4] [5] , suggesting that changes in CPT II could be relevant for fatty acid oxidation. Despite these results, the role of LCFAs in the expression of CPT II remains unclear. Thus whereas L-CPT I expression is induced by LCFAs at the transcriptional level in hepatocytes of foetal rats [6] , or during the foetal-neonatal transition [7, 8] , the activity, and mRNA levels of CPT II, are already high in the livers of term fetuses. These levels remain high throughout suckling and weaning, regardless of the fat content of the solid diet [8] .
The expression of several genes involved in intra-and extracellular lipid metabolism, especially in peroxisomal and mitochondrial β-oxidation, is controlled by ligand-activated receptors collectively referred to as peroxisome proliferator-activated receptors (PPARs) [9] . These receptors are members of the nuclear receptor superfamily and are activated by a wide array of peroxisome proliferators as well as by natural and synthetic fatty acids [10, 11] , anti-diabetic drugs [12] , prostaglandin J # [13] and leukotriene B % [14] . Activated PPAR, as a heterodimer with retinoid X receptor (RXR), binds to specific cis-acting elements termed peroxisome proliferator-responsive elements (PPREs) [15] [16] [17] . The consensus PPREs consist of a direct repeat of the sequence AGGTCA separated by 1 nucleotide (DR1) and flanked by an A\T-rich sequence. The previously described PPREs [18] contain a highly conserved first half-site and a less-conserved second half-site, flanked by the A\T-rich sequence. These peculiarities have been described as conferring polarity to the binding of the nuclear receptor heterodimer [17, 18] . Thus PPAR binds to the poorly conserved half-site of the DR1, because it interacts with the A\T-rich flanking sequence of the element, while RXR binds to the conserved half-site of the DR1 (reviewed in [19] ).
Recent studies on the gene encoding medium-chain acyl-CoA dehydrogenase have shown that several members of the nuclear receptor superfamily interact specifically with the nuclear receptor-responsive element NRRE-1, including chicken ovalbumin promoter [20] , PPAR [21] , retinoic acid receptor\RXR [22] , apolipoprotein regulatory protein-1 and hepatocyte nuclear factor-4 [23] and oestrogen-related receptor α (ERRα) [24] . During development and in the hypertrophied and failing heart, the rate of fatty acid utilization and the expression of genes encoding fatty acid oxidation, such as medium-chain acyl-CoA dehydrogenase, are similar and correlate with changes in PPAR and chicken ovalbumin promoter transcription factor (COUP-TF) expression. This suggests that the expression of PPAR and COUP-TF nuclear receptors controls the transcription of genes for fatty acid oxidation enzymes [25] . The interplay between nuclear receptors is also observed in the regulation of several genes such as the acyl-CoA synthetase [26] , M-CPT I [27] and mitochondrial 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase [28] [29] [30] .
Mice lacking PPARα show altered constitutive or induced expression of genes encoding several mitochondrial and peroxisomal fatty acid-catabolizing enzymes [31] . The expression of CPT II is increased in wild-type mice fed Wy-14,643 or ciprofibrate and this induction is lost in the PPARα-null animals [4, 5] . The constitutive expression of several fatty acid-utilization genes, including CPT II, was also examined in hearts of PPARα −/− mice [31] ; the expression of CPT II is decreased in these animals. Starvation also induces the immunoreactive CPT II protein by 2.3-fold in the kidney of wild-type mice, and this induction is lost in the knock-out animal [2] . All these data are consistent with our findings of a PPRE in the 5h-flanking region.
Here we show by a chromatin immunoprecipitation (ChIP) assay that the CPT II gene promoter is occupied in i o by PPARα. We localized the PPRE in the human CPT II gene promoter. The sequence of this PPRE contains one half-site which is a perfect consensus sequence (TGACCT), but no clearly recognizable second half-site (CAGCAC), which appears to play a limited role in PPARα binding, followed by a conserved A\T flanking region. In addition we show that the orphan receptors COUP-TF I and ERRα also bind to this element, modulating the PPARα trans-activation of the CPT II promoter. These results confirm the relevance of nuclear receptors in the transcriptional control of mitochondrial fatty acid oxidation.
EXPERIMENTAL Plasmids
The human CPT II gene 5h-regulatory region was amplified using the oligonucleotides DH73 (5h-CTAAGATCAGGGATTGGG-GCGTGG-3h) and DH74 (5h-GGCTCCATCCTTGCGAGAC-TGTGG-3h), corresponding to positions k514 to k490 and j84 to j107, respectively, of the human CPT II gene [32] . Human genomic DNA was used as a template. The PCR product was digested with PstI\XbaI, and a product containing the human CPT II 5h-regulatory region from position k477 to j7 was cloned into pCAT-Basic (reporter plasmid from Promega encoding for chloramphenicol acetyltransferase) PstI\XbaI sites to generate the construct p477CPTIICAT. Using this construct as a template, a PCR fragment was amplified using oligonucleotides CATF (5h-CTTCCGGCTCGTATGTTGTG-3h ; complementary to positions j164 to j183 of pCAT-Basic) and DH221 (5h-ATATGAGATAAAGATAACATGTTATGCACAGTGC-AT-3h ; located between positions k29 to j7 of the CPTII gene) and cloned into the SmaI site of the pGL3 Basic reporter plasmid (encoding the firefly luciferase reporter gene ; Promega). The resulting construct was called pCPTIIA.
Deletion constructs of the 5h-regulatory region were formed as follows. pCPTIIB was formed by PCR amplification with pCPTIIA as a template, using primers DH173 (5h-AAATGCTgc-AGCCAAGAATGGATG-3h ; nucleotides in lower case were changed to provide a PstI site), corresponding to positions k286 to k263, and DH221, phosphorylating and cloning the product into the pGL3 Basic SmaI site. For plasmids pCPTIIC and pCPTIID, which were constructed in an identical manner, the forward primers DH175 (5h-CCGCTCtGcAGGGGCTTTC3h ; corresponding to co-ordinates k245 to k226) and DH 87 (5h-GCAGTAGCTcTGCAGGGTTCAGGG-3h ; corresponding to co-ordinates k138 to k112 ; where nucleotides in lower case were changed to provide a PstI site), respectively, and reverse primer DH221 were used. Plasmid pCPTIIE was constructed using primers DH291 (5h-gcacggctagCTAACAACAG-3h ; corresponding to co-ordinates k77 to k68) and CPT2Rev (5h-gaattcctcgaGATATGAGATAAAGATAACATG-3h ; position j8 to k14 ; nucleotides in lower case were added to provide NheI\XhoI sites at the 5h and 3h ends, respectively), digestion with NheI and XhoI and cloning into NheI and XhoI sites of pGL3 Basic.
The PPRE mutant construct pCPTIIA1M was generated by overlap-extension PCR [33] . The first PCR used forward primer DH294 (5h-ttgtgctagcTGAGGGATGATAGATCT-3h ; position k462 to k446 ; lower-case sequence was added to generate an NheI restriction site) and reverse primer DH293 (5h-CCGTGCTGAAaGcttTTGACATATAATGAC-3h ; position k82 to k112 ; nucleotides in underlined lower case correspond to those changed from the wild-type sequence). The second PCR used forward primer DH292 (5h-TATATGTCAAaagCtTTCAGCA-CGGATTAC-3h), which overlapped with DH293, and reverse primer DH221. After the subsequent overlap-extension reaction, the PCR product was phosphorylated and cloned into the pGL3 Basic SmaI site. The PPRE mutant construct pCPTIIAFM was generated in the same way, using oligonucleotides DH294 and DH221, and the overlapping oligonucleotides DH524 (5h-TGACCTTCAGCACGcccaACTAACAAC-3h) and DH525 (5h-GTtgggCGTGCTGAAGGTCATTGACATA-3h). The heterologous promoter plasmid was constructed using pGL3-Promoter [which contains the simian virus 40 (SV40) promoter upstream of the firefly luciferase reporter gene]. It contains a fragment corresponding to co-ordinates k108 to k75 and was formed by cloning the oligonucleotide DH206 (5h-TTATATGTCAAT-GACCTTCAGCACGGATTACTAA-3h) annealed to DH207 (5h-cgcgTTAGTAATCCGTGCTGAAGGTCATTGACATATAagct-3h ; the lower-case sequences were added to generate SacI and MluI cohesive ends) into the pGL3-Promoter SacI and MluI sites. The resulting plasmid was called pCPTII-PPRE. Automatic sequencing using the fluorescent terminator kit (PerkinElmer) was performed to check all constructs.
Cell culture and transfections
HepG2 and HeLa cells were cultured in minimal essential medium supplemented with non-essential amino acids and 10 % fetal bovine serum. CaCo-2 cells were cultured in Dulbecco's modified Eagle's medium supplemented with non-essential amino acids and 10 % fetal bovine serum. Cells were co-transfected by the calcium phosphate method [34, 35] with 2 µg of the reporter CPT II-luciferase gene construct and 500 ng of eukaryotic expression vectors encoding PPARα, RXRα, COUP-TF I and ERRα (respectively : pSG5-mPPARα, pJCXR8, pRSHCOUP and pERRα) or an equal amount of salmon sperm DNA. In all experiments 40 ng of pRL (encoding the cytomegalovirus promoter and Renilla luciferase) was included as an internal control in transfections. Experiments with ligands included either vehicle (DMSO) or ligand (1 µM 9-cis-retinoic acid, 30 µM Ly-171883 or Wy-14,643). Cell extracts were prepared by passive lysis and luciferase assays were performed following the instructions of the Dual Luciferase Reporter Assay System (Promega). Luciferase activity was measured using the TD-20\20 Luminometer (Turner Designs).
In vitro transcription and translation
cDNAs for the receptors [mouse PPARα, human RXRα (hRXRα), human COUP-TF I and mouse ERRα] and pSG5 as an unprogrammed lysate were transcribed and translated using a commercially available kit according to the instructions of the manufacturer (Promega).
Expression and purification of human PPARs in Escherichia coli
Human PPARα and δ were amplified by reverse-transcriptase PCR [36] using total RNA from HepG2 cells treated and untreated with 125 µM linoleic acid (Sigma) for 24 h, respectively. PPARγ2 was amplified by PCR using the Human Fat Cell Quick-Clone TM cDNA (Clontech). Oligonucleotides for PCR amplification were designed in agreement with the human PPARs' described sequences (L02932, L07592 and U79012 for human PPARα, δ and γ2, respectively) and were designated ALPHA.F (5h-ctgcaggtcgactGCGATGGTGGACACGG-3h ; position k3 to j17 ; taking j1 as translation initiation) and ALPHA.R (5h-ctgcaggcggccgCTCAGTACATGTCCCTGTAG3h ; j1407 to j1387) for human PPARα, DELTA.F (5h-ctgcagcccgggTCAGCCATGGAGCAGCCAC-3h ; k6 to j12) and DELTA.R (5h-ctgcaggcggccgcTTAGTACATGTCCTTGT-AG-3h ; j1325 to j1306) for human PPARδ, and GAMMA.2F (5h-ctgcagcccgggGCTGTTATGGGTGAAAC-3h ; k6 to j11) and GAMMA.R (5h-ctgcaggcggccgcCTAGTACAAGTCCTT-GTAG-3h ; j1517 to j1498) for human PPARγ2. The lowercase sequences in these six primers were added to generate restriction sites for cloning. The PPARα PCR product was digested with SalI and NotI, cloned into pBluescriptSKj (Stratagene) SalI\NotI sites and sequenced. Finally, the SalI\NotI insert was liberated from pBSSKj and cloned into SalI\NotI sites of pGEX-4T-2 (Amersham Biosciences) to yield plasmid pGEXhPPARα. PPARδ and PPARγ2 PCR products were digested with SmaI and NotI, cloned into pBSSKj SmaI\NotI sites and sequenced. The SmaI\NotI insert was finally liberated from pBSSKj and cloned into pGEX-4T-2 SmaI\NotI sites to yield plasmids pGEXhPPARδ and pGEXhPPARγ2 respectively. E. coli BL-21 cells were transformed with the pGEXhPPARα, pGEXhPPARδ or pGEXhPPARγ2 expression plasmids. Cells were cultured and induced with isopropyl β--thiogalactoside as described by the supplier. Purification of the recombinant proteins was assessed as described previously [37] .
Electrophoretic mobility shift assay (EMSA)
Unprogammed lysate (2 µl) or mouse PPARα with or without hRXRα (2 µl) or hCOUP-TF I synthesized in itro was preincubated on ice for 10 min in 10 mM Tris\HCl, pH 8, 0.05 % (v\v) Nonidet P-40, 6 % glycerol, 1 mM dithiothreitol and 2 µg of poly(dI-dC). Mouse ERRα synthesized in itro was preincubated on ice for 10 min in 10 mM Tris\HCl, pH 8, 40 mM KCl, 0.05 % (v\v) Nonidet P-40, 6 % glycerol, 1 mM dithiothreitol, 2 µg of poly(dI-dC), 0.1 µg of BSA and 0.1 µg of salmon sperm DNA. For competition experiments the indicated molar excess of unlabelled double-stranded probe, relative to the labelled probe, was included during preincubation. For supershift analysis 2 µg of anti-PPARα or anti-COUP-TF I antibodies (Santa Cruz Biotechnology) was included during preincubation. For binding quantification, labelled probes were incubated with 400 ng of the E. coli-expressed and -purified recombinant PPARs and 2 µl of hRXRα synthesized in itro. The FLPPRE and FL1MPPRE probes resulted from the annealing of oligonucleotides DH206 and DH207, and DH292 and DH293, respectively. The WTPPRE probe resulted from the annealing of oligonucleotides DH489 (5h-ctagcTGACCTTCAGCACGGATTAC-3h) and DH490 (5h-tcgaGTAATCCGTGCTGAAGGTCAg-3h ; nucleotides in lower case in these primers and those shown below were added to provide NheI\XhoI sites at the 5h and 3h ends, respectively). The 1MPPRE probe resulted from the annealing of oligonucleotides DH491 (5h-ctagcaagCtTTCAGCACGGATTAC-3h ; the nucleotides in underlined lower case correspond to those changed from the wild-type sequence) and DH492 (5h-tcgaGTAATCCGTGCTGAAgGcttg-3h). The 2MPPRE probe resulted from the annealing of oligonucleotides DH493 (5h-ctagcTGACCTTCAGtACG-GATTAC-3h) and DH494 (5h-tcgaGTAATCCGTaCTGAAGGTCAg-3h), and FMPPRE resulted from the annealing of oligonucleotides DH495 (5h-ctagcTGACCTTCAGCACGcccaAC-3h) and DH496 (5h-tcgaGTtgggCGTGCTGAAGGTCAg-3h). The ERRsite probe was produced by the annealing of oligonucleotides DH588 (5h-ctagCAATGACCTTCAGC-3h) and DH589 (5h-tcga-GCTGAAGGTCATTG-3h). $#P-labelled probe (2 ng) was then added and the incubation was continued for 15 min at room temperature. The final volume for all reactions was 20 µl. Samples were electrophoresed at 4 mC on a 4.5 % polyacrylamide gel in 0.5iTBE buffer (45 mM Tris\45 mM boric acid\1 mM EDTA, pH 8.0). The retarded complexes were quantified using Storm PhosphorImager2 (Amersham Biosciences).
ChIP assays
CaCo-2 cells were fixed with formaldehyde at 37 mC for 10 min. Cells were harvested and incubated in nuclear lysis buffer [5 mM Pipes\KOH, pH 8.0, 85 mM KCl and 0.5 % (v\v) Nonidet P-40] for 10 min in ice. Nuclei were pelleted by centrifugation, and soluble chromatin was further isolated as described in [38] . The chromatin solution was sonicated and precleared with salmon sperm DNA\Protein G-Sepharose. The precleared chromatin solution was incubated for 16 h with 20 µg of anti-PPARα antibody (Santa Cruz Biotechnology) or 20 µg of preimmune serum. Immune complexes were collected with salmon sperm DNA\Protein G-Sepharose, washed and eluted in 1 % SDS\ 0.1 M NaHCO $ . Cross-links were reversed and chromatinassociated proteins were digested with proteinase K. The DNA was recovered by phenol\chloroform extraction and ethanol precipitation. Pellets were resuspended in 50 µl of water and 10 µl aliquots were used as template for PCR reaction. Primers used for promoter amplification were DH176 (5h-CTCCTGCA-GAAATCCTTTCTAATATCC-3h, located at position k186 to k159 of the human CPT II 5h-regulatory region) and DH221. Primers used for exon 4 amplification were DH582 (5h-TCCAG-GCACATCTGAAGTAC-3h ; j1321 to j1340 of the human CPT II cDNA) and DH583 (5h-ACGGCAGTAGAGCCATCC-TTG-3h ; position j1618 to j1598 of the human CPT II cDNA).
RESULTS

The human CPT II gene contains a PPARα-response element
The expression of luciferase from a construct containing the 5h-regulatory sequence of the human CPT II gene (k477 to j7) is increased by co-transfection of a mouse PPARα expression vector (pSG5-mPPARα) and a hRXRα expression vector (pJCXR8) in HeLa cells ( Figure 1A) . Addition of PPARα ligands (Ly-171883 or Wy-14,643) and RXRα ligands (9-cisretinoic acid) further increased the transcriptional activity of the promoter.
PPARα binds the human CPT II gene promoter in vivo
We were able to immunoprecipitate the human CPT II gene promoter using an antibody against human PPARα (Figure 2) , amplifying a region from k186 to j7 of the human CPT II gene 5h-regulatory region by PCR. The PCR product was detected in input and in anti-hPPARα-immunoprecipitated chromatin, but was not detected when preimmune serum was incubated with
Figure 2 PPARα occupies the CPT II gene promoter in vivo
ChIP assays were carried out by immunoprecipitating CaCo-2 cell chromatin with an antibody against human PPARα (PPARα Ab) or preimmune serum (PI). Immunoprecipitated chromatin was amplified with oligonucleotides DH176 and DH221, which amplified from k186 to j7 (promoter), or oligonucleotides DH582 and DH583, which amplified the human CPT II exon 4. Input represents 1 % of total chromatin. A negative control (H 2 O) for PCR is also shown. The data are representative of three independent experiments. chromatin. No PCR product was detected in the immunoprecipitated samples when oligonucleotides for exon 4 amplification were used. These results indicate that the immunoprecipitation of the human CPT II gene 5h-regulatory region with anti-hPPARα is specific.
Localization of the PPRE
To locate the PPRE, progressively larger 5h deletions of the 5h-flanking region of CPT II were used ( Figure 1B ). These constructs were tested in co-transfection experiments with pSG5-mPPARα using human hepatoma HepG2 cells. Nucleotides up to position k138 were deleted without loss of the response to PPARα, which was eliminated by further deletion up to nucleotide k80 ( Figure 1C ). Sequence comparison of CPTII promoter from position k138 to k80 with a consensus PPRE ( Figure 3A) shows, besides the inverted repeat IR-1, previously identified as a functional farnesoid X-activated receptor (FXR)\RXR-binding site [39] , the presence of a putative PPRE in which the second half-site was poorly conserved. Figure 3(B) shows that a probe including this putative element (FLPPRE) did not form a retardation complex with either mouse PPARα ( Figure 3B , lane 3) or hRXRα ( Figure 3B, lane 9) alone, whereas the inclusion of both mouse PPARα and hRXRα in the EMSA resulted in a prominent complex ( Figure 3B, lane 4) . The specificity of binding was studied by competition assays. Figure 3 (B) also shows that the addition of increasing amounts of an unlabelled CPTII probe was able to eliminate the labelled complex ( Figure 3B , lanes 5 and 6). However, a probe in which the conserved half-site was mutated (FL1MPPRE) was unable to produce PPARα\RXRα complex (results not shown) or to eliminate the complex formed with the wild-type probe ( Figure 3B, lanes 7 and 8) .
When the characterized sequence was inserted into a pGL3-Promoter vector (a plasmid containing the luciferase gene under the control of an SV40 promoter) this sequence conferred PPARα responsiveness to the otherwise unresponsive SV40 promoter ( Figure 4A ), indicating that this sequence is sufficient to mediate the PPARα response. These data indicate that the PPRE is located between k108 and k75, a region which contains an imperfect direct repeat separated by one nucleotide, followed by an AT-rich sequence (TGACCTTCAGCACGGATTAC) corresponding to co-ordinates k97 to k78, which seems to mediate the response to PPARα. The introduction of four point mutations into the conserved half-site eliminated the binding of PPARα ( Figure 3B) , and when introduced in the context of pCPTIIA it obliterates both basal activity and the induction by PPARα ( Figure 4B ). These data indicate that the localized element is necessary for both maintaining basal activity of the promoter and mediating the PPARα response. The introduction of four point mutations into the A\T-rich flanking region, which also eliminated the binding of PPARα (see below), abolished the response to PPARα, but did not affect the basal activity of the promoter.
COUP-TF I and ERRα bind to the same DNA region in the CPT II gene as PPARα and repress the induction of the CPT II gene by PPARα
We performed gel mobility-shift assays to analyse whether other members of the nuclear receptor superfamily bind to the PPRE of the CPT II gene ( Figure 5A ). For this experiment we used a probe (WTPPRE) that only contained the DR1 and the flanking region of the element (positions k97 to k78). COUP-TF I and ERRα transcribed and translated in itro produced a prominent complex with a DNA probe containing the DNA sequence to which PPARα\RXRα bind ( Figure 5A , lanes 3 and 4, respectively). In transactivation experiments both COUP-TF I and ERRα were able to repress the transcriptional activity of the promoter and to repress the activation produced by PPARα\ RXRα ( Figure 5B ). To study the binding of these factors by supershift assays with nuclear extracts, we used CaCo-2 cell nuclear extracts as a source of these proteins. In the presence of CaCo-2 nuclear extracts, the WTPPRE probe generated a specific complex (a in Figure 5C ) that was eliminated in the presence of a 200-fold molar excess of WTPPRE probe ( Figure  5C, lane 7) , but was not affected by the addition of 200-fold molar Figure 5C ) was also detected that could correspond to ERRα. When we used a probe containing just the ERRsite (the first direct repeat of the element followed by three flanking nucleotides, identical with the ERR consensus), which does not bind PPAR or COUP-TF I, complex b ( Figure 5C , lane 9) was clearly detected. This band has a similar mobility to the in itro-synthesized mouse ERRα complex ( Figure 5C, lane 10) .
Characterization of human CPT II gene PPRE
To characterize the sequence of the human CPT II gene PPRE, we performed gel-shift assays ( Figure 6 ) with wild-type and mutated probes, in the presence of PPARα, δ and γ2 and RXRα. Probe 1MPPRE contained four point mutations in the first halfsite of the responsive element, and this mutation dramatically reduced the binding of all PPAR isotypes to the element. Probe 2MPPRE contained a point mutation in the second half-site of the element and caused about a 40 % reduction in the binding of PPARδ and γ2, but no significant differences were found between the binding of PPARα to the wild-type probe and to the second half-site mutated probe. Finally, introduction of four point mutations in the A\T-rich flanking region caused at least a 65 % decrease in the binding of all PPARs. Binding of COUP-TF I to the wild-type and mutated probes was also quantified. Mutation of the conserved half-site almost abolished the binding of COUP-TF I to the element. Mutation of the second half-site reduced the binding by 60 %, but mutation of the A\T-rich flanking site of the element had no significant effect on the COUP-TF-I binding to the element. Binding of ERRα was dramatically affected by mutation of the conserved half-site, but the mutations in the second half-site and flanking region did not affect the binding.
DISCUSSION
The human CPT II gene 5h-regulatory region responds to PPARα\RXRα ( Figure 1A ). The addition of PPARα and RXRα ligands slightly but significantly increased the transcriptional activity of the promoter. Luciferase reporter constructs containing deletions of the promoter downstream from position k138 did not respond to PPARα in cell culture ( Figure 1C ). Using EMSA (Figure 3 ), PPARα-unresponsive SV40 promoter chimaeric constructs ( Figure 4A ) and site-directed mutagenesis ( Figure 4B ), we localized an element sufficient and necessary to mediate the PPARα response. This element is also necessary for maintaining the basal transcriptional activity of the human CPT II gene promoter in HepG2 cells. The results concerning the basal expression of CPT II in the PPARα-knockout mice are controversial. Aoyama et al. [4] and Watanabe et al. [40] reported that the inmunoreactive CPT II protein present in the liver of mice lacking PPARα was not diminished when compared with the wild-type mice, while Hashimoto et al. [2] reported a 50 % decrease of CPT II protein in the liver of PPARα-knockout mice and a 30 % decrease in kidney. In hearts of PPARα −/− mice the constitutive expression of CPT II gene is reduced by about 77 % compared with the wild-type animals [40] . The fact that HepG2 cells express low levels of PPARα [41] and that the mutation of the element in the conserved half-site abolishes the basal activity of this gene in HepG2 cells ( Figure 4B ) raises the possibility that factors other than PPARα are involved in maintaining the basal promoter activity of the gene throughout the binding to the same cis element. According to that, introduction of mutations on the flanking region affected the PPAR binding but did not affect the basal activity of the promoter, indicating that the basal activity is maintained by other factor(s) different from PPAR in HepG2 cells.
The knockout data suggest that the importance of PPARα in the regulation of the CPT II gene expression depends on the tissue in which CPT II is expressed, pointing to an interplay of factors regulating the expression of the gene. Besides the heterodimer PPAR\RXR, the sequence described in this report can be recognized by other members of the nuclear receptor superfamily. COUP-TF I and ERRα ( Figure 5 ), nuclear orphan receptors involved in the control of fatty acid-metabolism-related genes, are able to bind to the CPT II promoter in itro and repress the activation induced by PPARα, providing a way of modulating the PPARα induction. We wanted to demonstrate that nuclear receptors present in nuclear extract from cells expressing PPARα, RXRα, COUP-TF I and ERRα were able to bind the characterized element. We used nuclear extracts from CaCo-2 cells because low levels of endogenous PPARα have been described in HepG2 cells [41] , and we detected good levels of endogenous PPARα in CaCo-2 cells by reverse-transcriptase PCR (results not shown). Using nuclear extracts from CaCo-2 cells we demonstrate that PPARα and COUP-TF I bind to the same element ( Figure 5C ). When a probe (ERRsite) that does not bind PPAR or COUP-TF I but contains the ERRα-binding site was used, a complex appears that could correspond to ERRα. These results raise the possibility of competition between the PPARα\ RXRα heterodimer and either COUP-TF I or ERRα binding to the same region and controlling the CPT II gene expression.
We found that the human CPT II gene PPRE was located between positions k98 and k78. This sequence appears to be a novel PPRE. It contains one half-site which is a perfect consensus sequence (TGACCT) and has no clearly recognizable second half-site (CAGCAC), containing only one match to the consensus, followed by an A\T-rich flanking region. The second half-site is the least conserved of all the PPREs described thus far, as only one base is conserved. To further characterize the element, we performed EMSA with mutated probes (Figure 6 ) and purified human PPARα, δ and γ2. As in most of the described PPREs [18] , the CPT II PPRE binds more efficiently to PPARγ2 than α or δ. Introducing mutations in the first halfsite dramatically diminished the binding of the three PPAR isotypes, due to the incapability of RXR for binding to the mutated half-site. Mutation of the single conserved nucleotide of the second half-site had no significant effect on the binding of PPARα, but reduced the PPARδ and γ2 binding. This result indicates that the binding of PPARα to the PPRE does not depend on the conservation of a second half-site, while PPARδ and γ2 binding depends more on its conservation. Mutation of the flanking region decreased the binding of all PPARs. These data confirm that, as in other PPREs, the binding of PPARs to the element is more dependent on the flanking region composition than on the second half-site itself. The introduction of mutations in the first half-site or flanking region in the context of the whole promoter (Figure 4 ) abolished the PPARα responsiveness of the promoter, correlating function and binding. The binding of COUP-TF I to the element is extremely dependent on the first half-site conservation and completely independent on the composition of the flanking region. ERRα has been described to bind as a monomer to an extended half-site (5h-TCAAGGTCA-3h [24, 42] ). In agreement with this, mutations in the first half-site dramatically affected the binding, but mutation in the second half-site and flanking region did not affect it. Thus, the first half-site seems to be a common element extremely important for the binding of different nuclear receptors to the element, and this explains its conservation. The novelty of the characterized element is the presence of a poorly conserved second half-site, whose composition is not relevant for the binding of PPARα.
In order to demonstrate the in i o relevance of this partially conserved element, we performed ChIP assays using an antibody against PPARα (Figure 2) . We performed the assay in CaCo-2 cells, due to the low levels of endogenous PPARα described in HepG2 and the good levels of endogenous PPARα detected in CaCo-2. We immunoprecipitated the human CPT II gene promoter using the anti-PPARα antibody, indicating that the described element binds PPARα in i o.
Although PPARα has been proposed as a mediator of the transcriptional effects of LCFAs and fibrates (reviewed in [19] ), in foetal hepatocytes LCFAs had no effect on the level of the CPT II transcript, which was already high in these cells, in contrast with the strong induction it exerts on L-CPT I mRNA. However, the peroxisome proliferator, clofibrate, increased the levels of both CPT II and L-CPT I mRNA in foetal hepatocytes [6] . The lack of induction of CPT II in response to fatty acids in foetal hepatocytes or after birth may be associated with the high expression of this gene observed at these stages. Recent studies [43] propose that fatty acids may regulate transcription in a PPARα-independent way, suggesting independent pathways for peroxisome proliferators and LCFA responses. This could explain that CPT II is a target gene for PPARα but not for LCFAs. However, this explanation seems unlikely as the PPARα-knockout loses the CPT II induction by starvation in kidney [2] , indicating that the adaptive response to fasting, and probably to LCFAs, is mediated by PPARα.
Mice lacking the PPARα show an altered constitutive or induced expression of genes encoding several mitochondrial fatty acid-catabolizing enzymes [31] . Although hepatic fatty acid oxidation is dramatically impaired in fasted PPARα-null mice, the L-CPT I mRNA levels are not so clearly diminished [44, 45] , indicating that PPARα does not play a crucial role in the L-CPT I response to fasting. If the expression of the L-CPT I in the knockout is not the cause of the diminished β-oxidation during fasting, then a low rate of fatty acid oxidation could be caused by the lack of induction of CPT II. Recent results point out that impaired β-oxidation could also be caused by the lack of induction of the HMG-CoA mitochondrial synthase, which leads to the accumulation of acetyl-CoA or\and β-oxidation intermediates that are strong inhibitors of acyl-CoA dehydrogenases [46] . This study shows that the human CPT II gene is a target of PPARα. This nuclear receptor mediates its effect through a PPRE that contains a poorly conserved second half-site and a conserved first half-site that seems to act as a core for the binding of other nuclear receptors such as COUP-TF I or ERRα. These results, together with the identification of a functional FXR\ RXR-binding element [39] sharing one half-site with the proposed PPRE, indicate that an interplay of factors is regulating the human CPT II gene expression and confirm the relevance of nuclear receptors controlling mitochondrial fatty acid oxidation.
